ENO2 is a cytoplasmic glycolytic enzyme that can function as a novel metabolic biomarker for predicting pancreatic ductal adenocarcinoma metastasis and as a metabolic therapeutic target 35. The gene discussed is HK1; the disease is pancreatic ductal adenocarcinoma.